Aion Therapeutic Inc (CSE:AION) announced Thursday that it has filed four new patent applications related to preparations of medicinal and psychedelic mushrooms.
In a statement, the company said the patent applications include the use of medicinal mushrooms for the treatment of human cancers including breast cancer, use of combination medical cannabis and medicinal mushroom preparations for the treatment of interstitial cystitis and other bladder diseases, and methods for producing emulsions and nano-emulsions for increasing bioavailability in these formulations.
Aion said the new additions increase its intellectual property portfolio to a current total of nine patent applications with more expected in the very near future.
READ: Aion Therapeutic files five patent applications covering medical cannabis/mushroom combinations
"Based on these recent discoveries, we believe that it may be possible to improve upon the effectiveness of standard treatments for certain cancers including breast cancer as well as offering a new therapy for the painful chronic condition known as interstitial cystitis," said Dr Herbert Fritsche, chief science officer of Aion Therapeutic and former director of clinical chemistry at the University of Texas, MD Anderson Cancer Center.
"We intend to announce the details of these very exciting discoveries now that the patents have been filed."
Aion CEO Graham Simmonds noted that in conjunction with its licensed medical cannabis partner Apollon Formularies Jamaica Ltd, Aion is leveraging its unique position to combine medical cannabis and medicinal mushroom compounds for the treatment of serious diseases including cancer.
"In addition, Aion will be utilizing psilocybin with certain cannabinoids to treat additional conditions such as major depressive disorder (MDD) at our new Aion Center for Psychedelic Psychiatry directed by Dr Winston De La Haye in Jamaica,” he said.
“Strategically locating our operations in Jamaica allows Aion to operate and conduct clinical trials in a federally legal environment and thereby having a significant head start on patentable therapeutic formulation discoveries combining mushrooms (including psilocybin) and tetrahydrocannabinol (THC) with other medicinal mushroom and medical cannabis compounds while this type of combinatorial research with psilocybin remains illegal in most of the world."
Contact the author: patrick@proactiveinvestors.com
Follow him on Twitter @PatrickMGraham